These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30210775)

  • 1. Probing key elements of teixobactin-lipid II interactions in membranes.
    Wen PC; Vanegas JM; Rempe SB; Tajkhorshid E
    Chem Sci; 2018 Sep; 9(34):6997-7008. PubMed ID: 30210775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding Modes of Teixobactin to Lipid II: Molecular Dynamics Study.
    Liu Y; Liu Y; Chan-Park MB; Mu Y
    Sci Rep; 2017 Dec; 7(1):17197. PubMed ID: 29222455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teixobactin kills bacteria by a two-pronged attack on the cell envelope.
    Shukla R; Lavore F; Maity S; Derks MGN; Jones CR; Vermeulen BJA; Melcrová A; Morris MA; Becker LM; Wang X; Kumar R; Medeiros-Silva J; van Beekveld RAM; Bonvin AMJJ; Lorent JH; Lelli M; Nowick JS; MacGillavry HD; Peoples AJ; Spoering AL; Ling LL; Hughes DE; Roos WH; Breukink E; Lewis K; Weingarth M
    Nature; 2022 Aug; 608(7922):390-396. PubMed ID: 35922513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Killing Mechanism of Teixobactin against Methicillin-Resistant Staphylococcus aureus: an Untargeted Metabolomics Study.
    Hussein M; Karas JA; Schneider-Futschik EK; Chen F; Swarbrick J; Paulin OKA; Hoyer D; Baker M; Zhu Y; Li J; Velkov T
    mSystems; 2020 May; 5(3):. PubMed ID: 32457238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teixobactin analogues reveal enduracididine to be non-essential for highly potent antibacterial activity and lipid II binding.
    Parmar A; Iyer A; Prior SH; Lloyd DG; Leng Goh ET; Vincent CS; Palmai-Pallag T; Bachrati CZ; Breukink E; Madder A; Lakshminarayanan R; Taylor EJ; Singh I
    Chem Sci; 2017 Dec; 8(12):8183-8192. PubMed ID: 29568465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural studies suggest aggregation as one of the modes of action for teixobactin.
    Öster C; Walkowiak GP; Hughes DE; Spoering AL; Peoples AJ; Catherwood AC; Tod JA; Lloyd AJ; Herrmann T; Lewis K; Dowson CG; Lewandowski JR
    Chem Sci; 2018 Dec; 9(47):8850-8859. PubMed ID: 30627403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elucidation of the Teixobactin Pharmacophore.
    Yang H; Chen KH; Nowick JS
    ACS Chem Biol; 2016 Jul; 11(7):1823-6. PubMed ID: 27232661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding Site and Potency Prediction of Teixobactin and other Lipid II Ligands by Statistical Base Scoring of Conformational Space Maps.
    Lungu CN; Diudea MV
    Curr Comput Aided Drug Des; 2018; 14(1):29-34. PubMed ID: 28969532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping the targeted membrane pore formation mechanism by solution NMR: the nisin Z and lipid II interaction in SDS micelles.
    Hsu ST; Breukink E; de Kruijff B; Kaptein R; Bonvin AM; van Nuland NA
    Biochemistry; 2002 Jun; 41(24):7670-6. PubMed ID: 12056898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing Equipotent Teixobactin Analogues against Drug-Resistant Bacteria and Discovering a Hydrophobic Interaction between Lipid II and Teixobactin.
    Zong Y; Sun X; Gao H; Meyer KJ; Lewis K; Rao Y
    J Med Chem; 2018 Apr; 61(8):3409-3421. PubMed ID: 29629769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin.
    Münch D; Engels I; Müller A; Reder-Christ K; Falkenstein-Paul H; Bierbaum G; Grein F; Bendas G; Sahl HG; Schneider T
    Antimicrob Agents Chemother; 2015 Feb; 59(2):772-81. PubMed ID: 25403671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Dynamics Insight into the Lipid II Recognition by Type A Lantibiotics: Nisin, Epidermin, and Gallidermin.
    Panina I; Taldaev A; Efremov R; Chugunov A
    Micromachines (Basel); 2021 Sep; 12(10):. PubMed ID: 34683220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docking and molecular dynamics simulations of the ternary complex nisin2:lipid II.
    Mulholland S; Turpin ER; Bonev BB; Hirst JD
    Sci Rep; 2016 Feb; 6():21185. PubMed ID: 26888784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of type A lantibiotics with undecaprenol-bound cell envelope precursors.
    Müller A; Ulm H; Reder-Christ K; Sahl HG; Schneider T
    Microb Drug Resist; 2012 Jun; 18(3):261-70. PubMed ID: 22432708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mode of action of lipid II-targeting lantibiotics.
    Bauer R; Dicks LM
    Int J Food Microbiol; 2005 May; 101(2):201-16. PubMed ID: 15862882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Necessity of d-Thr in the New Antibiotic Teixobactin: A Molecular Dynamics Study.
    Liu Y; Li W; Chan-Park MB; Mu Y
    J Chem Inf Model; 2019 Apr; 59(4):1575-1583. PubMed ID: 30855952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysine Scanning of Arg
    Abdel Monaim SAH; Jad YE; Ramchuran EJ; El-Faham A; Govender T; Kruger HG; de la Torre BG; Albericio F
    ACS Omega; 2016 Dec; 1(6):1262-1265. PubMed ID: 30023506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Syntheses of potent teixobactin analogues against methicillin-resistant Staphylococcus aureus (MRSA) through the replacement of l-allo-enduracididine with its isosteres.
    Parmar A; Iyer A; Lloyd DG; Vincent CS; Prior SH; Madder A; Taylor EJ; Singh I
    Chem Commun (Camb); 2017 Jul; 53(55):7788-7791. PubMed ID: 28650495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular modeling of Gram-positive bacteria peptidoglycan layer, selected glycopeptide antibiotics and vancomycin derivatives modified with sugar moieties.
    Ślusarz R; Szulc M; Madaj J
    Carbohydr Res; 2014 May; 389():154-64. PubMed ID: 24685455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual Targeting of Cell Wall Precursors by Teixobactin Leads to Cell Lysis.
    Homma T; Nuxoll A; Gandt AB; Ebner P; Engels I; Schneider T; Götz F; Lewis K; Conlon BP
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6510-6517. PubMed ID: 27550357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.